Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Insights into CD8+ T Cells & Lupus

Lara C. Pullen, PhD  |  July 6, 2021

As for supplementation with NAD+, he feels the current laboratory research does not yet make a strong case for use of the supplement in humans. Of note, however, the NAD+ precursor vitamin nicotinamide riboside has been evaluated in healthy middle-aged and older adults and preliminary research indicates it is well tolerated and may reduce blood pressure and arterial stiffness.2

“That would be very helpful because our patients get atherosclerosis at such a young age,” agrees Dr. Thomas. However, he explains NAD+ is required by all cells in the body, and he is unclear how its supplementation would specifically benefit patients with lupus. Instead, he encourages his patients to supplement with vitamin D, turmeric and ginger—all of which have been associated with some positive benefits in clinical trials of patients with lupus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

  1. N Buang, L Tapeng, V Gray, et al. Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nature Comm. 2021 Mar 31;12(1):1980.
  2. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018 Mar 29;9(1):1286.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CD8+ T CellsSLEsystemic lupus erythematosus (SLE)

Related Articles

    The Type I Interferon Pathway’s Influence in Connective Tissue Disease

    July 18, 2019

    Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences